An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancerSia V. Lindskrog, Lars Dyrskjøt, Frederik Prip et al.|Nature Communications|2021Cited by 381
Treatment of High-grade Non–muscle-invasive Bladder Carcinoma by Standard Number and Dose of BCG Instillations Versus Reduced Number and Standard Dose of BCG Instillations: Results of the European Association of Urology Research Foundation Randomised Phase III Clinical Trial “NIMBUS”Marc‐Oliver Grimm, Raymond G. Schipper, Wim P.J. Witjes et al.|European Urology|2020Cited by 132
Prognostic Impact of a 12-gene Progression Score in Non–muscle-invasive Bladder Cancer: A Prospective Multicentre Validation StudyLars Dyrskjøt, Torben F. Ørntoft, Thomas Reinert et al.|European Urology|2017Cited by 100
Molecular Markers Increase Precision of the European Association of Urology Non–Muscle-Invasive Bladder Cancer Progression Risk GroupsKim E.M. van Kessel, Ellen C. Zwarthoff, Kirstin A. van der Keur et al.|Clinical Cancer Research|2018Cited by 92
Comprehensive genomic characterization of early-stage bladder cancerFrederik Prip, Lars Dyrskjøt, Philippe Lamy et al.|Nature Genetics|2025Cited by 30